Cargando…

Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma

Detalles Bibliográficos
Autores principales:	Graham, Charlotte Elizabeth, Jozwik, Agnieszka, Quartey-Papafio, Ruby, Ioannou, Nikolaos, Metelo, Ana M., Scala, Carlo, Dickson, Glenda, Stewart, Orla, Almena-Carrasco, Maria, Peranzoni, Elisa, Ramsay, Alan G., Patten, Piers E. M., Pertel, Thomas, Farzaneh, Farzin, Dupouy, Sandra, Pepper, Andrea, Benjamin, Reuben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632681/ https://www.ncbi.nlm.nih.gov/pubmed/34145373 http://dx.doi.org/10.1038/s41375-021-01324-z

Ejemplares similares

Allogeneic CAR-T Cells: More than Ease of Access?
por: Graham, Charlotte, et al.
Publicado: (2018)

Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma
por: Kuhnl, Andrea, et al.
Publicado: (2022)

Lymphoma immunotherapy: Efficacy, safety and accessibility to CAR-T therapy for lymphomas
por: Borchmann, Peter
Publicado: (2018)

CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
por: Mohty, Razan, et al.
Publicado: (2022)

Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors
por: Metelo, Ana M., et al.
Publicado: (2022)

CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
por: Su, Lihe, et al.
Publicado: (2022)

CAR-Based Approaches to Cutaneous T-Cell Lymphoma
por: Scarfò, Irene, et al.
Publicado: (2019)

CAR-T Cell Therapy for Classical Hodgkin Lymphoma
por: Katsin, Mikalai, et al.
Publicado: (2023)

Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
por: Dupouy, Sandra, et al.
Publicado: (2022)

CAR T-Cell Therapy for Large B-Cell Lymphoma
por: Alencar, Maritza C.
Publicado: (2019)

CAR T-Cells for CNS Lymphoma: Driving into New Terrain?
por: Karschnia, Philipp, et al.
Publicado: (2021)

CAR T-Cell therapy for the management of mantle cell lymphoma
por: Huang, Zoufang, et al.
Publicado: (2023)

Recent advances in CAR T-cell therapy for lymphoma in China
por: Che, Yuxuan, et al.
Publicado: (2023)

CAR-T Cell Therapy in Large B Cell Lymphoma
por: Testa, Ugo, et al.
Publicado: (2023)

Autocrine-based selection of ligands for personalized CAR-T therapy of lymphoma
por: Stepanov, Alexey V., et al.
Publicado: (2018)

Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T
por: Crees, Zachary D., et al.
Publicado: (2021)

New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL
por: Iqbal, Madiha, et al.
Publicado: (2021)

Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas
por: Atar, Daniel, et al.
Publicado: (2022)

The race is on: bispecifics vs CAR T cells in B-cell lymphoma
por: Gurumurthi, Ashwath, et al.
Publicado: (2023)

CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma
por: Ostojska, Magdalena, et al.
Publicado: (2023)

Mechanistic Modeling of the Interplay Between Host Immune System, IL-7 and UCART19 Allogeneic CAR-T Cells in Adult B-cell Acute Lymphoblastic Leukemia
por: Derippe, Thibaud, et al.
Publicado: (2022)

The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
por: Meier, Jeremy A., et al.
Publicado: (2022)

CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives
por: Sheikh, Semira, et al.
Publicado: (2022)

Fulminant Cardiotoxicity in a Patient With Cardiac Lymphoma Treated With CAR-T Cells
por: Koch, Christian, et al.
Publicado: (2022)

Metabolic Imaging in B-Cell Lymphomas during CAR-T Cell Therapy
por: Linguanti, Flavia, et al.
Publicado: (2022)

CAR-T Therapy in Lymphoma Patients With Coexisting Cardiomyopathy or Cardiac Lymphomatous Involvement
por: Ng, Choon Ta, et al.
Publicado: (2023)

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma
por: Raghunandan, Sharmila, et al.
Publicado: (2023)

A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy
por: Li, Tongjuan, et al.
Publicado: (2019)

CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain
por: Li, Tongjuan, et al.
Publicado: (2020)

CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope
por: Hopfinger, Georg, et al.
Publicado: (2019)

Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy
por: Fang, Penny Q., et al.
Publicado: (2021)

Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells
por: Wang, Hongxia, et al.
Publicado: (2021)

Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)
por: Tbakhi, Bushra, et al.
Publicado: (2022)

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma
por: Siddiqi, Tanya, et al.
Publicado: (2021)

Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells
por: Feng, Jia, et al.
Publicado: (2022)

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma
por: Zurko, Joanna, et al.
Publicado: (2022)

CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse
por: Vu, Khoan, et al.
Publicado: (2022)

CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma
por: Wittibschlager, Valerie, et al.
Publicado: (2023)

Prediction of lymphoma response to CAR T cells by deep learning-based image analysis
por: Tong, Yubing, et al.
Publicado: (2023)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jo062jlu306jg4mpuv7h81rinr